In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Rusfertide | Conjugate Dulaglutide (Trulicity) | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Conjugate | |
| Area | Weight and metabolic | Weight and metabolic | |
| Evidence | |||
| Amount of evidence | 78 | 1,919 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 21 (21 in people) | 488 (445 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 10 · 4 active | 124 · 15 active19 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
The FDA label for Mimrylo says: “Erythrocytosis in adults with polycythemia vera”
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Rusfertide | Dulaglutide (Trulicity) |
|---|---|---|
| Adverse eventsWhole body | 1616 | 27823543 |
| PharmacokineticsPharmacology |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The FDA label for Trulicity says: “A GLP-1 analog fused to an IgG4 Fc region, approved for type 2 diabetes and specified cardiovascular risk reduction”
2323
44404 |
| MortalityWhole body | 11 | 2323 |
|---|
| Heart functionCardiovascular | 66 | 171421 |
|---|
| Liver fat and liver functionLiver | 11 | 20191 |
|---|
| Patient-reported outcomesWhole body | 11 | 1717 |
|---|
| Blood biochemical markersWhole body | 1313 | 11 |
|---|
| Overall treatment effectWhole body | 22 | 44 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Dulaglutide (Trulicity) differs from GLP-1 (7-37) at 246 positions.
What is different
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Rusfertide | Dulaglutide (Trulicity) |
|---|---|---|
| PharmacokineticsPharmacologyCompared as: value in the arm that got the peptide, in ng/ml | 1100 ng/mL Cmax (geometric mean) · rusfertide 90 mg Dose studied: 90 mgn = 602025 | No comparable result 22 randomized-trial results measure it in another way or another unit. |
| Patient-reported outcomesWhole bodyCompared as: value in the arm that got the peptide, in points | No randomized trial result 1 result from other study designs. | −1.2 points Treatment satisfaction score change Dose studied: 0.75 mg/week24 weeksn = 632023 |
| MortalityWhole bodyCompared as: value in the arm that got the peptide, in % | No comparable result 1 randomized-trial result measure it in another way or another unit. | 10.8% Mortality Placebo: 12% Dose studied: 1.5 mg weeklyMedian follow-up 5.4 yearsn = 9,9012019 |
| Adverse eventsGastrointestinalCompared as: value in the arm that got the peptide, in % | No comparable result 11 randomized-trial results measure it in another way or another unit. | 82% Adverse events Dose studied: 0.75 mg weekly52 weeksn = 652020 |
| Heart functionCardiovascularCompared as: difference from placebo, in ms | −2 to 1.8 ms Placebo-corrected ΔQTcF (ΔΔQTcF) LS mean Dose studied: 90 mgn = 602025 | No comparable result 7 randomized-trial results measure it in another way or another unit. |
1100 ng/mL
Cmax (geometric mean) · rusfertide 90 mg
Dose studied: 90 mgn = 602025
No comparable result
22 randomized-trial results measure it in another way or another unit.
No randomized trial result
1 result from other study designs.
−1.2 points
Treatment satisfaction score change
Dose studied: 0.75 mg/week24 weeksn = 632023
No comparable result
1 randomized-trial result measure it in another way or another unit.
10.8%
Mortality
Placebo: 12%
Dose studied: 1.5 mg weeklyMedian follow-up 5.4 yearsn = 9,9012019
No comparable result
11 randomized-trial results measure it in another way or another unit.
82%
Adverse events
Dose studied: 0.75 mg weekly52 weeksn = 652020
−2 to 1.8 ms
Placebo-corrected ΔQTcF (ΔΔQTcF) LS mean
Dose studied: 90 mgn = 602025
No comparable result
7 randomized-trial results measure it in another way or another unit.
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 10 trials, ranked by phase, then posted results and enrollment: 2 ongoing · 1 completed · 2 with posted results · source ClinicalTrials.gov (opens in a new tab)
Protagonist Therapeutics, Inc.293 participants11 Apr 2022 to est. 31 Aug 2028
Polycythemia Vera
Protagonist Therapeutics, Inc.46 participants22 Jan 2024 to est. 1 Apr 2027
Polycythemia Vera
Protagonist Therapeutics, Inc.16 participants19 Mar 2020 to 15 Feb 2022
Hereditary Hemochromatosis
Top 3 of 124 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Eli Lilly and Company13,299 participants29 May 2020 to 12 Jun 2025
Type 2 Diabetes Mellitus
Eli Lilly and Company9,901 participants22 Jul 2011 to 21 Aug 2018
Cardiovascular Disease · Diabetes Mellitus, Type 2
Eli Lilly and Company1,842 participants5 Apr 2018 to 10 Oct 2019
Diabetes Mellitus, Type 2
19 more mention it but do not test it. They only measure it or name it in their text.